| Name | Title | Contact Details |
|---|
Lower Manhattan Dialysis Admin is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acuderm is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Our primary focus is helping physicians conquer even the most difficult disease states, including arterial calcium, given the complications it presents for the millions who suffer from peripheral arterial disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes.
At Mach7, our purpose is simple: to deliver to healthcare professionals the tools they need to help their patients achieve better health outcomes. Every day, medical practitioners face the challenge of bringing together an immense amount of patient data from multiple disparate sources while also finding a way to make sense of it. They must contend with issues like non-consolidated image storage, labor-intensive and inefficient workflows, and multiple viewers for different specialties and image types. With these obstacles in mind, Mach7 has built innovative solutions from the ground up that can integrate multiple systems, enable clinical collaboration, deliver vendor neutral archiving, provide enterprise-wide universal viewing, modernize legacy PACS, and more. Mach7 is focused on removing the technology limitations that inhibit the free flow of patient information and access to the complete patient medical record. We differ from many other companies in the industry by building an integrated imaging ecosystem where all technologies work together in harmony. Because we are built as an integration platform first, we give you the freedom to use the technologies that are important to your physicians and patients, even if they are from another vendor. This also means we offer the independence and flexibility to deploy these as individual components or a comprehensive end-to-end enterprise imaging platform. Through this, we help organizations increase their efficiency, achieve profound operational cost savings, leverage their existing IT investments, improve the experience for patients and medical professionals, and, ultimately, support healthier outcomes.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.